Hepatocellular effects of cyclosporine A and its derivative SDZ IMM 125 in vitro

Journal of Pharmacology and Experimental Therapeutics

Volumn 284, Issue 3, 1998, Pages 817-825

  Wolf, Armin ^a   Schramm, Ursula ^a   Fahr, Alfred ^b   Aicher, Lothar ^a   Cordier, André ^a   Trommer, Wolfgang E ^c   Fricker, Gert ^d  

^a NOVARTIS PHARMA AG   (Switzerland)

^b Inst F Pharmazeut Technol B   (Germany)

^c Rheinland Pfälzische Technische Universität Kaiserslautern Landau   (Germany)

^d Inst F Pharmazeut Technol B   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CALCIUM ION; CYCLOSPORIN A; CYCLOSPORIN A [8 DEXTRO O (2 HYDROXYETHYL)SERINE]; LACTATE DEHYDROGENASE; LIPOSOME; SODIUM ION; TAUROCHOLIC ACID;

ANIMAL CELL; ANIMAL TISSUE; ANISOTROPY; ARTICLE; BILE FLOW; CHOLESTASIS; CONTROLLED STUDY; DIFFUSION COEFFICIENT; DRUG CYTOTOXICITY; DRUG UPTAKE; ENZYME ACTIVITY; LIPOPHILICITY; LIVER CELL DAMAGE; MALE; MEMBRANE PERMEABILITY; NONHUMAN; PARTITION COEFFICIENT; PRIORITY JOURNAL; RAT;

ANIMALS; BILE; BILE ACIDS AND SALTS; CALCIUM; CELLS, CULTURED; CYCLOSPORINE; CYCLOSPORINS; IMMUNOSUPPRESSIVE AGENTS; L-LACTATE DEHYDROGENASE; LIVER; MALE; RATS; RATS, WISTAR; SODIUM;

EID: 0031936575     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (47)

1. Anwer MS, Kroker R and Hegner D (1966) Cholic acid uptake into isolated rat hepatocytes. Hoppe-Seyler Zeitschr Physiol Chem 357:1477-1486.
2. Atkinson K, Biggs J, Dodds A and Concannon A (1983) Cyclosporin-associated hepatoxicity after allogenic marrow transplantation in man. Differentiation from other causes of post transplant liver disease. Transplant Proc 25:2761-2767.
3. Azer SA and Stacey NH (1991) Effect of cyclosporin A in vivo on cholyltaurine uptake by rat hepatocytes. Biochem Pharmacol 42:2053-2057.
4. Borel J, Feurer C, Gubler HU and Stähelin H (1976) Biological effects of cyclosporin A: A new antilymphocytic agent. Agents Actions 6:468-475.
5. Bradford M (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
6. Cary NC (1989) SAS/STAT User's Guide, version 6, 4th edition, Volume 2, SAS Institute Inc., Cary, NC.
7. Chervinsky DS, Brecher ML, Baker RM, Hoelcle MJ and Tebbi CK (1993) Reversal of C1300 murine neuroblastoma multidrug resistance by cremophor EL, a solvent for cyclosporin A. Cancer Biother 8:67-75.
8. Cohen DJ, Loertscher R, Rubin M, Tilney NL, Carpenter CB and Strom TB (1984) Cyclosporin: A new immunosuppressive agent for organ transplantation. Ann Intern Med 101:667-682.
9. Damjanovich S, Aszalos A, Mulhern S, Szöllösi J, Balazs M, Tron L and Fulwyler MJ (1987) Cyclosporin A depolarizes human lymphocytes: earliest observed effect on cell metabolism. Eur J Immunol 17:763-768.
10. Deneke U and Rittersdorf W (1984) Evaluation of the Refloquant GPT (ALT) reagent carriers with Reflotron (Abstract). Clin Chem 30:1009.
11. Deneke U, Rittersdorf W and Werner W (1985) Performance data of Reflotron-GOT (AST) dry chemistry test for Reflotron [Abstract]. Clin Chem 31:921.
12. Donatsch P, Mason J, Richardson BP and Ryffel B (1992) Toxicologic evaluation of the new cyclosporin derivative, SDZ IMM-125, in a comparative, subchronic toxicity study in rats. Transplant Proc 24 (4 suppl 2):39-42.
13. Dudeja PK, Anderson KM, Harris JS, Buckingham L and Coon JS (1995) Reversal of multidrug resistance phenotype by surfactants: relationship to membrane lipid fluidity. Arch Biochem Biophys 319:309-315.
14. Dunnett CW (1955) A multiple comparison procedure for comparing several treatments with a control. J Am Statist Assoc 50:1096-1121.
15. Dunnett CW (1980) Pairwise multiple comparisons in the homogeneous variance, unequal sample size case. J Am Statist Assoc 75:789-795.
16. Ellis CN, Gorsulowsky DC, Hamilton TA, Billings JK, Brown MD, Headington JT, Cooper KD, Baadsgaard O, Duell EA, Annesley TM, Turcotte JG and Voorhees JJ (1986) Cyclosporin improves psoriasis in a double blind study. JAMA 256:3110-3116.
17. Fahr A, Holz M, Fricker G (1995) Liposomal formulations of cyclosporin A: Influence of lipid type and dose on pharmacokinetics. Pharmaceut Res 12:1189-1198.
18. Farthing MJG, Clark ML, Pendry A, Sloane J and Alexander P (1981) Nature of the toxicity of cyclosporin A in the rat. Biochem Pharmacol 30:3311-3316.
19. Fjallskog ML, Frii L and Bergh J (1994) Paclitaxel-induced cytotoxicity - the effects of cremophor EL (castor oil) on two human breast cancer cell lines with aquired multidrug resistant phenotype and induced expression of the permeability glycoprotein. Eur J Cancer 30A:687-690.
20. Fricker G, Dubost V, Schwab D, Bruns C and Thiele C (1994) Heterogeneity in hepatic transport of somatostatin analog octapeptides. Hepatology 20:191-200.
21. Hiestand PC, Graber M, Hurtenbach U, Herrmann P, Cammisuli S, Richardson BP, Eberle MK, Donatsch P, Ryffel B and Borel JF (1993) New cyclosporin derivative SDZ IMM-125: In vitro and in vivo pharmacologic effects and toxicologic evaluation. Transplant Proc 25 (1 Pt. 1):691-692.
22. Kahan BD (1989) Cyclosporin. N Engl J Med 321:1725-1738.
23. Kehrer JP (1993) Free radicals as mediators of tissue injury and disease. Crit Rev Tox 23:21-48.
24. Kukongviriyapan V and Stacey NH (1988) Inhibition of cholyltaurine transport by cyclosporin A in cultured rat hepatocytes. J Pharmacol Exp Ther 247:685-689.
25. LeGrue S, Friedman AW and Kahan BD (1983) Binding of cyclosporin by human lymphocytes and phospholipid vesicles. J Immunol 131:712-718.
26. MacDonald RC, MacDonald RI, Menco BPM, Takeshita K, Subbarao NK and Hu LR (1991) Small-volume extrusion apparatus for preparation of large unilamellar vesicles. Biochim Biophys Acta 1061:297-303.
27. Mason J (1990) The pathophysiology of sandimmune (cyclosporin) in man and animals. Pediat Nephrol 4:554-574.
28. 2+ - ionophores. Biochim Biophys Acta 886:353-360.
29. Moseley RH, Johnson TR and Morrissette JM (1990) Inhibition of bile acid transport by cyclosporin A in rat liver plasma membrane vesicles. J Pharmacol Exp Ther 253:974-980.
30. Orrenius S (1993) Mechanisms of oxidative cell damage, in Free Radicals: From Basic Science to Medicine, (Poli G, Albano E and Dianzani MU eds) pp 47-64, Birkhäuser Verlag, Basel.
31. Rodger RSC, Turney JH, Haines I, Michael J, Adu D and McMaster P (1983) Cyclosporin and liver function in renal allograft recipients. Transplant Proc 15(suppl. 1/2):2754-2756.
32. Rogers AJ and Kahan BD (1984) Mechanism of action and clinical applications of cyclosporins in organ transplantation. Clin Allergy Immunol 4:217-258.
33. Roman ID, Monte MJ, Gonzalez-Buitrago JM, Esteller A and Jiménez R (1990) Inhibition of hepatocytary vesicular transport by cyclosporin A in the rat: Relationship with cholestasis and hyperbilirubinemia. Hepatology 12:83-91.
34. Ruetz S, Fricker G, Hugentobler G, Winterhalter K, Kurz G and Meier PJ (1987) Isolation and characterization of the putative canalicular bile salt transport system of rat liver. J Biol Chem 262:11324-11330.
35. Satterthwaite FW (1946) An approximate distribution of estimates of variance components. Biomet Bull 2:110-114.
36. Schade RR, Guglielmi A, Van Thiel DH, Thomson ME, Warty V, Griffith B, Sanghvi A, Bahnson H and Hardesty R (1983) Cholestasis in heart transplant recipients treated with cyclosporin. Transplant Proc 25:2757-2760.
37. Scheffe H (1959) The Analysis of Variance, John Wiley & Sons, Inc., New York.
38. Schramm U, Fricker G, Wenger R and Miller DS (1995) P-glycoprotein-mediated secretion of a fluorescent cyclosporin analgue by teleost renal proximal tubules. Am J Physiol 268:F46-F52.
39. Schramm U, Fricker G, Buscher H-P, Gerok W and Kurz G (1993) Fluorescent derivatives of bile acids. III. Uptake of 7β-NBD-NCT into isolated hepatocytes by the transport systems for cholyltaurine. J Lipid Res 34:741-757.
40. Stone BG, Udani M, Sanghvi A, Warty V, Plocki K, Benedetti CD and van Thiel DH (1987) Cyclosporin A induced cholestasis: the mechanism in a rat model. Gastroenterology 93:344-351.
41. Stone BG, Warty V, Dindzans V and Van Thiel D (1988) The mechanism of cyclosporin-induced cholestasis in the rat. Transplant Proc 20(suppl 3):841-844.
42. Williams GM and Gunn JM (1974) Long term culture of adult rat liver epithelial cells. Exp Cell Res 89:139-142.
43. Witkamp L, Zonneveld IM, Jung EG, Schopf RE, Christophers E, Grossmann R, Meffert H, Belaich S, Mahrle G, Van Joost T, Stoof T, Bos JD, Mayer H, Taesch S, Feutren G (1995) Efficacy and tolerability of multiple-dose SDZ IMM-125 in patients with severe psoriasis. Br J Dermatol 133:95-103.
44. Wolf A, Clemann N, Frieauff W, Ryffel B, Cordier A (1994) Role of oxidative oxygen formation in the cyclosporin A mediated impairment of renal functions. Transplant Proc 26:2902-2907.
45. Wolf A, Trendelenburg C-F, Diez-Fernandez C, Pricto P, Houy S, Trommer WE, Cordier A (1997) Cyclosporine A-induced oxidative stress in rat hepatocytes. J Pharm Exp Ther 280:1328-1334.
46. Ziegler K and Frimmer M (1986) Cyclosporin A and a diaziridine derivative inhibit the hepatocellular uptake of cholate, phalloidin and rifampicin. Biochim Biophys Acta 855:136-142.
47. +-dependent cholyltaurine uptake in basolateral (sinusoidal) rat liver plasma membrane vesicles. J Pharmacol Exp Ther 250:301-308.